Merck's Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) reported that Keytruda, its cancer drug, showed a significant improvement in disease-free survival for patients with advanced bladder cancer post-surgery in the Phase 3 AMBASSADOR/KEYNOTE-123 trial. The data, presented at the ASCO GU Symposium, indicated a 31% reduction in disease recurrence or death risk compared to observation. Median DFS was 29.0 months for Keytruda versus 14.0 months for observation. The overall survival endpoint has not yet reached statistical significance. Keytruda's safety profile remained consistent with no new safety signals. MRK shares rose 0.53% to $120.77.
January 26, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda demonstrated a significant improvement in disease-free survival for bladder cancer, which may positively influence the company's future earnings and reinforce the drug's market position.
Positive trial results for a leading drug like Keytruda can lead to increased sales and market share, reinforcing Merck's revenue stream. The lack of new safety concerns is also a positive sign, likely to boost investor confidence. The stock price uptick following the news suggests a positive market reaction, although the overall survival endpoint not reaching significance could temper some enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100